undamentalytics Newsletter
Sign in

Treace Medical Concepts, Inc. income statement

In fiscal 2025, Treace Medical Concepts, Inc. reported revenue of $213m, up 1.6% on the year before, operating income of −$54.2m (a -25.5% margin) and net income of −$59.0m, or −$0.93 per diluted share. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.

Income statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Revenue395794142187209213205
Cost of revenue812172635414342
Gross profit324578116152168170163
Research and development56101415212018
Selling and marketing263265105141148141136
General and administrative47183347566362
Operating income−41−17−35−51−56−54−54
Interest expense13445556
Income tax0000000—
Net income−4−4−21−43−50−56−59−60
Diluted EPS−$0.13−$0.12−$0.43−$0.77−$0.81−$0.90−$0.93−$0.93
Diluted shares (average)37m37m48m55m61m62m63m64m
EBITDA−32−16−33−46−47−44−46

EBITDA is operating income plus depreciation and amortisation. EPS and share counts are restated for stock splits. A dash means the company did not report the line for that period; expense lines are shown as reported, so they need not add up to the totals when a company reports other items between them.

Compare with peers

Head to head: SIBN vs TMCILAKE vs TMCIESTA vs TMCI

More: Health Care Equipment stocks compared, Health Care sector, rankings of US companies

Figures from Treace Medical Concepts, Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Treace Medical Concepts, Inc.